Skip to main content
CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
4.120
-0.170 (-3.96%)
At close: Apr 28, 2026, 4:00 PM EDT
4.180
+0.060 (1.46%)
After-hours: Apr 28, 2026, 7:24 PM EDT

CytomX Therapeutics Revenue

In the year 2025, CytomX Therapeutics had annual revenue of $76.20M, down -44.82%. CytomX Therapeutics had revenue of $663.00K in the quarter ending December 31, 2025, a decrease of -98.26%.

Revenue (ttm)
$76.20M
Revenue Growth
-44.82%
P/S Ratio
11.77
Revenue / Employee
$1,104,362
Employees
69
Market Cap
896.90M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202576.20M-61.90M-44.82%
Dec 31, 2024138.10M36.89M36.45%
Dec 31, 2023101.21M48.05M90.38%
Dec 31, 202253.16M15.85M42.48%
Dec 31, 202137.31M-31.12M-45.47%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Fortrea Holdings 2.72B
Maravai LifeSciences Holdings 185.74M
Geron 183.88M
Phathom Pharmaceuticals 175.11M
Xencor 125.58M
KalVista Pharmaceuticals 73.62M
Evommune 13.00M
Janux Therapeutics 10.00M
Revenue Rankings

CTMX News

More News